ATE369355T1 - Pyrimidinamid derivate und deren verwendung - Google Patents

Pyrimidinamid derivate und deren verwendung

Info

Publication number
ATE369355T1
ATE369355T1 AT03750639T AT03750639T ATE369355T1 AT E369355 T1 ATE369355 T1 AT E369355T1 AT 03750639 T AT03750639 T AT 03750639T AT 03750639 T AT03750639 T AT 03750639T AT E369355 T1 ATE369355 T1 AT E369355T1
Authority
AT
Austria
Prior art keywords
disease
derivatives
pyrimidinamide
benzoylaminophenyl
pyridyl
Prior art date
Application number
AT03750639T
Other languages
English (en)
Inventor
Paul Manley
Werner Breitenstein
Sandra Jacob
Pascal Furet
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE369355(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE369355T1 publication Critical patent/ATE369355T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
AT03750639T 2002-09-27 2003-09-26 Pyrimidinamid derivate und deren verwendung ATE369355T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0222514.2A GB0222514D0 (en) 2002-09-27 2002-09-27 Organic compounds

Publications (1)

Publication Number Publication Date
ATE369355T1 true ATE369355T1 (de) 2007-08-15

Family

ID=9944917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03750639T ATE369355T1 (de) 2002-09-27 2003-09-26 Pyrimidinamid derivate und deren verwendung

Country Status (24)

Country Link
US (1) US7655669B2 (de)
EP (1) EP1546127B1 (de)
JP (2) JP4463685B2 (de)
KR (2) KR20070098940A (de)
CN (1) CN100404528C (de)
AT (1) ATE369355T1 (de)
AU (1) AU2003270277B2 (de)
BR (1) BR0314797A (de)
CA (1) CA2499822C (de)
DE (1) DE60315479T2 (de)
DK (1) DK1546127T3 (de)
EC (1) ECSP055701A (de)
ES (1) ES2288615T3 (de)
GB (1) GB0222514D0 (de)
HK (1) HK1080459A1 (de)
MX (1) MXPA05003253A (de)
NO (1) NO20051966L (de)
NZ (1) NZ538930A (de)
PL (1) PL374443A1 (de)
PT (1) PT1546127E (de)
RU (1) RU2378267C2 (de)
SI (1) SI1546127T1 (de)
WO (1) WO2004029038A1 (de)
ZA (1) ZA200502304B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
WO2006024834A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
US7939541B2 (en) 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
MX2007002819A (es) * 2004-09-09 2007-08-14 Natco Pharma Ltd Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa.
CN1939910A (zh) * 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
ATE525073T1 (de) 2005-01-28 2011-10-15 Novartis Ag Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
MY146795A (en) 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
US20100216791A1 (en) * 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
DK2068938T3 (da) 2006-09-22 2011-04-04 Novartis Ag Optimering af behandlingen af Philadelphia-positiv leukæmi med ABL-tyrosinkinaseinhibitor imatinib
CN101622244A (zh) * 2006-11-03 2010-01-06 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
EA017269B1 (ru) * 2007-05-04 2012-11-30 Айрм Ллк ПРОИЗВОДНЫЕ ПИРИМИДИНА И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-kit И PDGFR
EP2152688A1 (de) 2007-05-04 2010-02-17 Irm Llc Verbindungen und zusammensetzungen als c-kit- und pdgfr-kinasehemmer
WO2008151183A1 (en) 2007-06-04 2008-12-11 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US8288540B2 (en) 2007-08-22 2012-10-16 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
KR101218926B1 (ko) 2007-08-22 2013-01-04 아이알엠 엘엘씨 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
CA2798143A1 (en) * 2010-05-11 2011-12-15 Mahesh Kandula Compound, synthesis, composition and uses thereof
EP3569598A1 (de) 2011-11-17 2019-11-20 Dana Farber Cancer Institute, Inc. Inhibitoren der c-jun-n-terminal-kinase (jnk)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3751742T3 (de) 1986-01-13 2002-11-21 American Cyanamid Co., Wayne 4,5,6-Substituierte 2-Pyrimidinamine
US5215989A (en) * 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
TW225528B (de) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
AU693475B2 (en) 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0025820D0 (en) 2000-10-20 2000-12-06 Novartis Ag Organic compounds
CA2446939C (en) 2001-05-16 2005-08-02 Matthias Stein-Gerlach Pyridylpyrimidine derivatives as effective compounds against prion diseases
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
CN100555083C (zh) 2003-12-23 2009-10-28 皇家飞利浦电子股份有限公司 用于浸入式光刻的可除去薄膜

Also Published As

Publication number Publication date
AU2003270277B2 (en) 2007-08-23
US20060142577A1 (en) 2006-06-29
MXPA05003253A (es) 2005-06-08
KR100876055B1 (ko) 2008-12-26
EP1546127A1 (de) 2005-06-29
JP4463685B2 (ja) 2010-05-19
CN1684951A (zh) 2005-10-19
US7655669B2 (en) 2010-02-02
ZA200502304B (en) 2006-04-26
ECSP055701A (es) 2005-05-30
SI1546127T1 (sl) 2008-08-31
NZ538930A (en) 2008-04-30
PT1546127E (pt) 2007-11-07
RU2005113153A (ru) 2006-11-10
CA2499822A1 (en) 2004-04-08
EP1546127B1 (de) 2007-08-08
JP5178681B2 (ja) 2013-04-10
KR20050047128A (ko) 2005-05-19
JP2010043113A (ja) 2010-02-25
CA2499822C (en) 2012-04-10
AU2003270277A1 (en) 2004-04-19
DE60315479D1 (de) 2007-09-20
CN100404528C (zh) 2008-07-23
GB0222514D0 (en) 2002-11-06
RU2378267C2 (ru) 2010-01-10
JP2006508064A (ja) 2006-03-09
NO20051966L (no) 2005-04-22
DK1546127T3 (da) 2007-12-10
BR0314797A (pt) 2005-07-26
HK1080459A1 (en) 2006-04-28
ES2288615T3 (es) 2008-01-16
WO2004029038A1 (en) 2004-04-08
DE60315479T2 (de) 2008-04-30
PL374443A1 (en) 2005-10-17
KR20070098940A (ko) 2007-10-05

Similar Documents

Publication Publication Date Title
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
WO2004005281A8 (en) Inhibitors of tyrosine kinases
TW200615266A (en) Organic compounds
ATE538794T1 (de) Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
ATE408601T1 (de) Fredericamycin-derivate
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
ATE233754T1 (de) Diphenyl-piperidin derivate
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
NO20030021D0 (no) Heterosykliske forbindelser som er inhibitorer for enzymet DPP-IV
DE60327249D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
TW200626591A (en) Amide derivatives, their manufacture and use as pharmaceutical agents
DE50304524D1 (de) Arzneimittel enthaltend substituierte 2,5-diaminomethyl-1h-pyrrole
ATE293107T1 (de) Luminacine analoge und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1546127

Country of ref document: EP

REN Ceased due to non-payment of the annual fee